



Company announcement

Avexa provides update on search for ATC marketing partners

Melbourne, Australia, Monday 10th December 2012: Australian biotechnology company Avexa Limited [ASX:AVX] today provided an update on the search for sales and marketing partners for apricitabine (ATC), their lead nucleoside analogue for the treatment of Human Immunodeficiency Virus (HIV) infection.

The search for partners has been undertaken in collaboration with Egamid Ltd, based in London, UK. Egamid were chosen because of their expertise, their global reach, their track record in these types of arrangements, their network, and their previous successful experience in working with Shire Pharmaceuticals Plc, the originator/licensor of ATC.

To date, a number of different companies have concluded the confidential due diligence process and have signed option agreements to market ATC in a number of jurisdictions. This includes agreements with:

- DEM Ilac (www.demilac.com.tr) a specialist pharmaceutical company servicing the Turkish and surrounding regions
- Dongwha Pharmaceuticals (www.dong-wha.co.kr) one of the major Korean pharmaceutical companies servicing Korea and other international regions
- LINK Healthcare (www.linkhealth.com.au), servicing the markets of Australia, New Zealand and South Africa
- Sanfer (www.sanfer.com.mx), a specialist pharmaceutical company servicing the Latin American region
- Shiner (www.shinerpharm.com), based in Taiwan and focused on hospital specialty products

The option agreements include a commitment from the partner to market ATC in specified jurisdictions, once Avexa has completed the remaining development and obtained regulatory approval.

Avexa has also secured further option agreements with other regional pharmaceutical companies, the details of which remain confidential owing to commercial sensitivities surrounding negotiation for similar market regions and the need to protect the confidentiality of their marketing plans and strategies from their competitors.

In addition to these, several other companies are progressing through the due diligence process, covering additional geographic regions such as Europe, Canada, Eastern Europe, Russia, India, Thailand, and China.

Avexa's Chairman, Iain Kirkwood said, "We are working hard to finalise these additional partners, as well as increasing our efforts to secure marketing partners for the USA"

**A V E X A**

Avexa Limited
ABN 53 108 150 750
576 Swan Street, Richmond
Victoria Australia 3121

Telephone 61 3 9208 4300
Facsimile 61 3 9208 4146
Website www.avexa.com.au

“This will ensure that we have global sales and marketing coverage for not only the established traditional large markets of the western economies in the northern hemisphere, but also the expanding markets of South America and Asia, where the treatment of HIV is accelerating”

About Avexa Limited

Avexa Limited is a Melbourne-based biotechnology company with a focus on discovery, development and commercialisation of small molecules for the treatment of infectious diseases. Avexa's key projects include apricitabine (ATC) for the treatment of drug resistant HIV, an HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections.

About Egamid Ltd., UK.

Dr. Giancarlo Mennella is the Founder & Managing Director of this Brokering Company which specialises in the in-out licensing of pharmaceuticals products and M&A support in the international healthcare sector with operations in Europe, USA, Japan and other Countries.

For more information:

Mr Iain Kirkwood
Avexa Chairman
Ph: +61 3 9208 4300

Dr Jonathan Coates
Avexa CSO and Interim CEO
Ph: +61 3 9208 4300

Richard Allen
Oxygen Public Relations
Ph: + 61 3 9915 6341

www.avexa.com.au